Ralph Ziegler1, Rudolf Eichholz2, Birgit Schulz3. 1. Diabetes Clinic for Children and Adolescents, Muenster, Germany rz@ziegler-muenster.de. 2. GKM Gesellschaft für Therapieforschung mbH, Munich, Germany. 3. A. Menarini Diagnostics, Division of Berlin-Chemie AG, Berlin, Germany.
Abstract
BACKGROUND: Using self-measurements of blood glucose (SMBG) is daily routine for patients with insulin-treated diabetes, however measuring ß-ketones in blood is not widespread. How the use of a combined device, which can measure both, is accepted in daily routine by patients and will lead to better glycemic control is not well studied. METHODS: This multicenter, prospective, noninterventional study assessed the impact of routine use of the GlucoMen® LX Plus on patient acceptance, usage and glycemic control among insulin-treated patients with diabetes mellitus type 1 and type 2. A1c and self-reported frequency of SMBG were evaluated at baseline and also postprandial SMBG, ß-ketone measurements, and use of reminders after 3 and 6 months of use. A total of 631 patients, 254 type 1/350 type 2 (27 no type specified), with mean (SD) baseline A1c 8.5% (1.5), age 54.6 (15.6) years, and 47.3% female were studied. RESULTS: Frequent use of SMBG at baseline led to a higher decrease in A1c at 6 month (V3): -0.3% if SMBG measured up to 1/day versus -0.9% in 4-6/day. Increase of SMBG frequency during the study showed also a negative correlation to A1c, 9.2% at V1 versus 7.6% at V3. Postprandial SMBG was done by 77.7% and ß-ketone measurements by 45.5% of all patients; the reminders were used by 33.4% and led to an increased frequency of SMBG at 6 months. CONCLUSIONS: A combined device for SMBG and ß-ketone measurements is well accepted by patients with insulin-treated diabetes and can lead through the avoidance or detection of ketoacidosis/increased frequency of SMBG and increased awareness of the patients to an improved glycemic outcome.
BACKGROUND: Using self-measurements of blood glucose (SMBG) is daily routine for patients with insulin-treated diabetes, however measuring ß-ketones in blood is not widespread. How the use of a combined device, which can measure both, is accepted in daily routine by patients and will lead to better glycemic control is not well studied. METHODS: This multicenter, prospective, noninterventional study assessed the impact of routine use of the GlucoMen® LX Plus on patient acceptance, usage and glycemic control among insulin-treatedpatients with diabetes mellitus type 1 and type 2. A1c and self-reported frequency of SMBG were evaluated at baseline and also postprandial SMBG, ß-ketone measurements, and use of reminders after 3 and 6 months of use. A total of 631 patients, 254 type 1/350 type 2 (27 no type specified), with mean (SD) baseline A1c 8.5% (1.5), age 54.6 (15.6) years, and 47.3% female were studied. RESULTS: Frequent use of SMBG at baseline led to a higher decrease in A1c at 6 month (V3): -0.3% if SMBG measured up to 1/day versus -0.9% in 4-6/day. Increase of SMBG frequency during the study showed also a negative correlation to A1c, 9.2% at V1 versus 7.6% at V3. Postprandial SMBG was done by 77.7% and ß-ketone measurements by 45.5% of all patients; the reminders were used by 33.4% and led to an increased frequency of SMBG at 6 months. CONCLUSIONS: A combined device for SMBG and ß-ketone measurements is well accepted by patients with insulin-treated diabetes and can lead through the avoidance or detection of ketoacidosis/increased frequency of SMBG and increased awareness of the patients to an improved glycemic outcome.
Authors: M Schütt; W Kern; U Krause; P Busch; A Dapp; R Grziwotz; I Mayer; J Rosenbauer; C Wagner; A Zimmermann; W Kerner; R W Holl Journal: Exp Clin Endocrinol Diabetes Date: 2006-07 Impact factor: 2.949
Authors: Richard M Bergenstal; Bruce W Bode; Ronald Tamler; Dace L Trence; Patricia Stenger; Holly C Schachner; Jeanellen Fullam; Scott Pardo; Taylor Kohut; William A Fisher Journal: Diabetes Technol Ther Date: 2012-10 Impact factor: 6.118
Authors: Mae Sheikh-Ali; Brad S Karon; Ananda Basu; Yogish C Kudva; Lisa A Muller; Jia Xu; W Frederick Schwenk; John M Miles Journal: Diabetes Care Date: 2008-01-09 Impact factor: 19.112
Authors: Jill H Simmons; Vincent Chen; Kellee M Miller; Janet B McGill; Richard M Bergenstal; Robin S Goland; David M Harlan; Joseph F Largay; Elaine M Massaro; Roy W Beck Journal: Diabetes Care Date: 2013-09-11 Impact factor: 19.112
Authors: Kellee M Miller; Roy W Beck; Richard M Bergenstal; Robin S Goland; Michael J Haller; Janet B McGill; Henry Rodriguez; Jill H Simmons; Irl B Hirsch Journal: Diabetes Care Date: 2013-02-01 Impact factor: 19.112